Participated · Equity · Feb 2026

Founded in 2021, Honest Health partners with hospitals and provider groups to navigate value-based, risk-bearing reimbursement models. Its platform supplies clinicians with actionable analytics, operational support, and shared-accountability structures that prioritize quality and cost containment over volume. Led by CEO Rob Bessler, M.D., and backed by founders from Rubicon Founders, the company combines deep clinical expertise with scalable technology infrastructure. Honest Health’s services include care coordination tools and performance dashboards designed to improve patient outcomes and financial performance for health systems. The company has rapidly gained traction, prompting sizable investor interest. Proceeds from its latest funding will be used to expand into additional U.S. markets, form new partnerships with payers and providers, and further develop its technology and service offerings. No revenue or user metrics were disclosed in the article, but management cites “measurable improvements” in outcomes and cost savings as evidence of early success.

Participated · Series A · Feb 2026

Atlas Oncology Partners partners with community oncology practices to deliver coordinated, patient-centered cancer care by embedding interdisciplinary teams of providers, nurses, patient navigators, and social workers directly into the practices. Its model combines patient navigation, psychosocial and supportive services, proactive care coordination, and expanded in-person and virtual clinical access. Uniquely, Atlas assumes full medical cost risk from payors and aligns incentives across patients, oncologists, and insurers to lower avoidable costs while enhancing outcomes. Founded and incubated by Rubicon Founders, the company seeks to solve fragmentation in cancer care and ease the financial burden on patients. With its platform, Atlas invests in partner operations to enable high-quality, value-based oncology at scale. The recent $28 million Series A financing strengthens the company’s balance sheet and will fund geographic expansion and further development of its clinical and operational infrastructure.

Led · Series B · Jan 2026

Founded in 2023, Indigo offers vertically integrated medical malpractice insurance that pairs deep domain expertise with its proprietary AI platform, Lux. Lux applies advanced machine-learning models to automate traditionally manual underwriting workflows, enabling faster, more precise coverage decisions for physicians and their brokers. In less than two years the company has grown to insure nearly 1,000 providers nationwide and has written over $10 million in premium, with 20 % of submissions already fully underwritten automatically. This technology-led approach both increases underwriting throughput and maintains disciplined risk selection, driving strong broker satisfaction. Indigo’s business model emphasizes reduced administrative overhead and improved pricing accuracy, which it believes will ultimately lower premiums for high-quality medical groups. The company plans to use fresh capital to expand R&D, enhance product capabilities, grow distribution partnerships, and scale operations. Backed by healthcare-focused investors, Indigo aims to redefine medical malpractice insurance through vertical AI and continued automation of complex specialty risk.

Participated · Series B · Sep 2025

Founded in 2022, Imagine Pediatrics operates one of the nation’s largest multidisciplinary pediatric practices focused on children with complex medical, behavioral, and social needs. Its proprietary technology platform connects families with round-the-clock virtual and in-home teams offering services ranging from pharmacy and nutrition to palliative care and social support. The company partners with health plans under value-based arrangements and has already completed nearly 300,000 patient encounters, caring for approximately 40,000 children nationwide. In 2024 alone, these programs cut emergency department visits and avoidable hospital admissions enough to save partners more than $65 million. Families endorse the service with a Net Promoter Score above 86, underscoring strong patient satisfaction. New capital will be used to accelerate national expansion, advance the technology platform, and drive further clinical innovation aimed at closing pediatric care gaps.

Led · Equity · Jan 2025

Caidya is a full-service clinical research organization with capabilities spanning regulatory strategy, medical affairs, clinical operations, data management, biometrics, pharmacovigilance, quality management and post-approval surveillance. The company touts a strategic footprint in 23 countries and regions and deep therapeutic expertise in oncology, hematology, rare and pediatric diseases. Caidya emphasizes white-glove services, an agile partnership model, and customized solutions to help biopharma sponsors conduct studies with greater efficiency. The company was launched through the merger of dMed and Clinipace in 2021 and positions itself to serve biopharma innovation across the Americas, Europe, and APAC. Caidya plans to use new capital to support continued organic expansion and to explore strategic acquisitions as part of its next phase of growth. The announced $165 million strategic growth investment signals external financial backing to accelerate that plan and expand its global operations.